Compare Lupin Ltd with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs SUN PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN SUN PHARMA LUPIN/
SUN PHARMA
 
P/E (TTM) x -65.2 19.2 - View Chart
P/BV x 1.9 2.0 94.9% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 LUPIN   SUN PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-19
SUN PHARMA
Mar-19
LUPIN/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs986679 145.3%   
Low Rs720375 191.9%   
Sales per share (Unadj.) Rs369.5121.1 305.0%  
Earnings per share (Unadj.) Rs13.413.4 100.2%  
Cash flow per share (Unadj.) Rs37.420.7 180.7%  
Dividends per share (Unadj.) Rs02.75 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs303.7172.6 176.0%  
Shares outstanding (eoy) m452.492,399.26 18.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.34.4 53.1%   
Avg P/E ratio x63.639.4 161.5%  
P/CF ratio (eoy) x22.825.5 89.6%  
Price / Book Value ratio x2.83.1 92.0%  
Dividend payout %020.6 0.0%   
Avg Mkt Cap Rs m386,0641,264,650 30.5%   
No. of employees `00017.717.5 101.0%   
Total wages/salary Rs m31,51359,671 52.8%   
Avg. sales/employee Rs Th9,453.816,608.1 56.9%   
Avg. wages/employee Rs Th1,782.03,409.6 52.3%   
Avg. net profit/employee Rs Th343.01,833.8 18.7%   
INCOME DATA
Net Sales Rs m167,182290,659 57.5%  
Other income Rs m3,64010,255 35.5%   
Total revenues Rs m170,822300,914 56.8%   
Gross profit Rs m28,82263,076 45.7%  
Depreciation Rs m10,85017,533 61.9%   
Interest Rs m3,0785,553 55.4%   
Profit before tax Rs m18,53450,246 36.9%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,400-12,144 28.0%   
Tax Rs m9,0176,009 150.1%   
Profit after tax Rs m6,06632,093 18.9%  
Gross profit margin %17.221.7 79.4%  
Effective tax rate %48.712.0 406.8%   
Net profit margin %3.611.0 32.9%  
BALANCE SHEET DATA
Current assets Rs m138,536310,692 44.6%   
Current liabilities Rs m61,299173,396 35.4%   
Net working cap to sales %46.247.2 97.8%  
Current ratio x2.31.8 126.1%  
Inventory Days Days8499 84.6%  
Debtors Days Days112112 100.8%  
Net fixed assets Rs m127,516232,477 54.9%   
Share capital Rs m9052,399 37.7%   
"Free" reserves Rs m136,517411,691 33.2%   
Net worth Rs m137,422414,091 33.2%   
Long term debt Rs m66,41715,226 436.2%   
Total assets Rs m279,494646,938 43.2%  
Interest coverage x7.010.0 69.9%   
Debt to equity ratio x0.50 1,314.4%  
Sales to assets ratio x0.60.4 133.1%   
Return on assets %3.35.8 56.2%  
Return on equity %4.47.8 56.9%  
Return on capital %8.910.2 87.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41466,025 90.0%   
Fx outflow Rs m22,28238,610 57.7%   
Net fx Rs m37,13227,415 135.4%   
CASH FLOW
From Operations Rs m16,66021,965 75.8%  
From Investments Rs m-32,825-6,813 481.8%  
From Financial Activity Rs m7,441-27,305 -27.3%  
Net Cashflow Rs m-8,724-8,442 103.3%  

Share Holding

Indian Promoters % 46.6 63.7 73.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 5.1 220.3%  
FIIs % 31.9 23.0 138.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 8.3 121.7%  
Shareholders   98,259 133,026 73.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 1,028 Points; Oil & Gas, FMCG and Metal Stocks Rally(Closing)

Indian share markets continued to trade in the green during closing hours and ended their day on a strong note, tracking global cues.

Related Views on News

SYNGENE INTERNATIONAL Surges by 7%; BSE HEALTHCARE Index Up 3.4% (Market Updates)

Mar 31, 2020 | Updated on Mar 31, 2020

SYNGENE INTERNATIONAL share price has surged by 7% and its current market price is Rs 245. The BSE HEALTHCARE is up by 3.4%. The top gainers in the BSE HEALTHCARE Index are SYNGENE INTERNATIONAL (up 6.7%) and ASTRAZENECA PHARMA (up 7.7%). The top losers are BLISS GVS PHARMA and NATCO PHARMA (down 0.3%).

LUPIN Surges by 5%; BSE HEALTHCARE Index Up 1.8% (Market Updates)

Mar 31, 2020 | Updated on Mar 31, 2020

LUPIN share price has surged by 5% and its current market price is Rs 590. The BSE HEALTHCARE is up by 1.8%. The top gainers in the BSE HEALTHCARE Index are LUPIN (up 5.1%) and PIRAMAL ENTERPRISES (up 6.8%). The top losers are THYROCARE TECHNOLOGIES (down 0.4%) and ABBOTT INDIA (down 0.6%).

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Mar 31, 2020 (Close)

TRACK LUPIN

LUPIN - TORRENT PHARMA COMPARISON

COMPARE LUPIN WITH

MARKET STATS